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Arenaviruses such as Lassa fever virus cause significant mortality in endemic areas and represent potential bioterrorist
weapons. The occurrence of arenaviral hemorrhagic fevers is largely confined to Third World countries with a limited
medical infrastructure, and therefore live-attenuated vaccines have long been sought as a method of choice for
prevention. Yet their rational design and engineering have been thwarted by technical limitations. In addition, viral
genes had not been identified that are needed to cause disease but can be deleted or substituted to generate live-
attenuated vaccine strains. Lymphocytic choriomeningitis virus, the prototype arenavirus, induces cell-mediated
immunity against Lassa fever virus, but its safety for humans is unclear and untested. Using this virus model, we have
developed the necessary methodology to efficiently modify arenavirus genomes and have exploited these techniques
to identify an arenaviral Achilles’ heel suitable for targeting in vaccine design. Reverse genetic exchange of the viral
glycoprotein for foreign glycoproteins created attenuated vaccine strains that remained viable although unable to
cause disease in infected mice. This phenotype remained stable even after extensive propagation in immunodeficient
hosts. Nevertheless, the engineered viruses induced T cell–mediated immunity protecting against overwhelming
systemic infection and severe liver disease upon wild-type virus challenge. Protection was established within 3 to 7 d
after immunization and lasted for approximately 300 d. The identification of an arenaviral Achilles’ heel demonstrates
that the reverse genetic engineering of live-attenuated arenavirus vaccines is feasible. Moreover, our findings offer
lymphocytic choriomeningitis virus or other arenaviruses expressing foreign glycoproteins as promising live-
attenuated arenavirus vaccine candidates.
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Introduction
Lymphocytic choriomeningitis virus (LCMV) represents
the prototype member of the arenavirus family. The genome
of these enveloped negative-strand RNA viruses [1] consists of
a small (S) and a large (L) segment, each of them expressing
two viral genes in an ambisense coding strategy (Figure 1).
The S segment codes for the viral nucleoprotein (NP,
approximately 63 kDa) and the glycoprotein (GP). The GP,
encoded in genome polarity, is synthesized as a precursor
protein GP-C (75 kDa) and posttranslational processing
generates GP1/GP2 complexes forming club-shaped projec-
tions on mature infectious virions. NP, encoded in anti-
genome polarity, is the most abundant viral protein and
encapsidates viral genomes and antigenomic replicative
intermediates. The L gene segment codes for a 200-kDa L
protein with characteristic hallmarks of all RNA dependent
RNA polymerases and for the small 11-kDa RING ﬁnger
protein Z that functions as the viral matrix protein [2].
Arenaviruses are widespread in various rodent species
populating the entire globe and several of them can cause
hemorrhagic fevers when accidentally transmitted to humans
[3]. In addition, arenaviruses causing hemorrhagic fever have
recently obtained much attention due to their potential use
in warfare and bioterrorism [4, 5]. Among them are Lassa
fever virus (LFV), found in West Africa, and the South
American viruses Junin, Machupo, and Guanarito that cause
Argentine, Bolivian, and Venezuelan hemorrhagic fever,
respectively. LFV, with 100,000 to 300,000 estimated human
infections and several thousand deaths, annually affects by far
the largest number of humans [3]. After its ﬁrst description in
the late 1960s, LF was thought of as a rare disease with high
case-fatality rate that was transmitted by contact in hospital
epidemics. This picture has changed dramatically since it has
been found that in rural areas of West Africa, LFV accounted
for approximately 10% of febrile illnesses and that seropre-
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human transmission in a more recent nosocomial outbreak
could largely be accredited to poor medical practice
including needle sharing [6]. Together with the failure of
LFV to spread outside the West African distribution of its
rodent reservoir Mastomys, this indicated that the virus cannot
efﬁciently sustain itself by human-to-human transmission [3].
Increasing numbers of imported cases due to traveling,
however, are reported from around the globe [7, 8].
Ribavirin, a nucleoside analog, represents the only cur-
rently available therapy for clinical application in LF but it
appears to be of limited efﬁcacy [9]. Hence, protective
vaccines are needed, but the viral immunobiology has
rendered their development a difﬁcult undertaking. Immu-
nization with inactivated virus has failed to induce neutraliz-
ing antibodies (nAbs) or to protect against LFV in animal
models [10], and convalescent serum transfer rarely increased
the survival rate of LFV-infected humans [9, 11]. Accordingly,
life-long protection against LFV in previously infected
human subjects is commonly accredited to cell-mediated
immunity [12, 13] and candidate vaccines should therefore
aim at inducing long-lived T cell memory.
A variety of vector systems have been tested as potential
vaccines for arenaviruses, among them DNA immunization
and recombinant salmonella [14, 15]. Engineered vaccinia
virusesexpressingeithertheGPorNPofLFVhavebeenshown
to confer guinea pigs and nonhuman primates with cell-
mediated immunity against lethal LFV challenge [16]. Un-
fortunately, the safety proﬁle of vaccinia virus and the high
HIVprevalencerateinWestAfricaprecludetheapplicationof
thisvaccinewhereitwouldbemostneeded[13].Theprotective
capacity of alphavirus-based vectors has been demonstrated in
guinea pigs [17], and very recently it was shown that a
recombinant vesicular stomatitis virus (VSV) expressing
LFV-GP protected nonhuman primates against LF [18]. In
the latter two studies, challenge infections were invariably
carried out 28 d after immunization. Thus the long-term
protective capacity of these vectors may require additional
testing, particularly for VSV that has served as a prototype
model infection eliciting only short-lived T cell mediated
protection [19]. In case of a bioterrorist attack or for health
care workers and military personnel transiently deployed to
endemic areas, the longevity of protection may be of less
importance. For the population of West Africa, however, this
will be a key criterion because of the local cumulative lifetime
risk of contracting LFV ([3], see also above).
As an alternative to recombinant vector systems, heterol-
ogous Old World arenaviruses would likely represent very
efﬁcient LFV vaccines. Mopeia virus (MV) and LCMV, and
recently also an LFV/MV reassortant, have been shown to
protect against LF in nonhuman primates [16, 20, 21] and
guinea pigs, respectively [22]. In the latter model, adoptive
transfer experiments could formally show that cross-protec-
tion was cell mediated. Cross-reactivity between LCMV and
LFV has also been demonstrated at the level of T cell clones
and single cytotoxic T cell (CTL) epitopes [23, 24]. Moreover,
the strategy of vaccinating with a closely related but less
pathogenic virus (heterologous immunity) has a famous
precedent in the eradication of smallpox by using vaccinia
virus. Yet the safety proﬁle of different LCMV and MV strains
for humans remains unclear and untested. We therefore
considered the possibility of using genetically engineered
LCM viruses with a molecularly deﬁned basis of attenuation as
long-sought live-attenuated arenavirus vaccines [5, 12, 25, 26].
The arenavirus GP mediates receptor binding and cell
entry, but additional roles in the viral life cycle including the
efﬁcient release of particles have recently been described (see
Discussion and [2, 27 30]). GP1 represents the only target for
virus neutralizing antibodies [1, 31], and we have documented
a critical role of the LCMV-GP in viral evasion from efﬁcient
nAb-mediated control [31]. Similar to LCMV in mice, human
LFV infection elicits commonly only vastly delayed and
relatively poorly nAb responses [11, 32]. Accordingly, only the
most potent convalescent sera confer passive protection
against virus challenge, and prevention of lethal disease seems
relatively virus isolate speciﬁc [11, 32]. Thus, cell-mediated
immunity is considered the mechanism of choice for vaccine
candidates [12]. a-Dystroglycan is the only characterized
cellular arenavirus receptor, and the ability of certain LCMV
isolates to cause overwhelming systemic infection in mice has
been correlated with their high afﬁnity binding to a-
dystroglycan [33]. Interestingly, also the GP of LFV exhibits
high afﬁnity for a-dystroglycan, lending support to spec-
ulations that GP-related properties could contribute to the
viral phenotype [33, 34]. Studies in guinea pigs and also in
monkeys have shown that determinants on the L genome
segment are primarily responsible for the viral ability to
cause hemorrhagic fever and that determinants on the S
segment of virulent viruses (e.g., LFV) were not sufﬁcient for
disease [21, 35]. While addressing the contribution of GP to
strain-speciﬁc differences in pathogenesis, a potential need
for features that are common to all arenaviral GPs had not
been addressed in these experiments. Thus, we hypothesized
that the reverse genetic exchange of the LCMV-GP for a
foreign surface determinant may attenuate the virus and
thereby may offer a general strategy for the directed
engineering of live-attenuated arenavirus vaccines.
We had previously reported on a recombinant LCM virus
(rLCMV/INDG) expressing the surface GP of vesicular
stomatitis virus serotype Indiana (INDG) instead of its own
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Synopsis
Arenaviruses such as Lassa fever virus (LFV) account for substantial
mortality in endemic Third World countries and represent potential
bioterrorist weapons. Live-attenuated vaccine strains would likely
represent an optimal strategy for prevention, but their rational
design and engineering have been thwarted by technical limita-
tions. As an additional difficulty, arenaviruses have only four genes,
all of which are needed for the infectious cycle. Unlike for other virus
families, attempts at deleting a ‘‘virulence gene’’ would therefore
interfere with the virus’ viability and thereby with its immunoge-
nicity. Using the prototype arenavirus as a model, the authors have
developed the necessary tools to investigate an alternative strategy
for tailoring of live-attenuated strains: Recombinants were engi-
neered to express a foreign envelope gene instead of the natural
one. Thereby, the virus was crippled but still viable. When testing
such ‘‘envelope-exchange’’ viruses in a mouse model, they failed to
cause disease. Nevertheless, they elicited rapid and long-lived
immunity against overwhelming infection and lethal disease upon
wild-type virus challenge. This delineates a novel general strategy
for the reverse genetic engineering of live-attenuated arenavirus
vaccines to be used in endemic areas or in case of a bioterrorist
attack.GP (schematically depicted in Figure 1 [31, 36]). rLCMV/INDG
exhibits attenuated growth in tissue culture ([31, 36], see also
Figure 5A), and unlike for wild-type LCMV (LCMVwt), it
elicits a rapid and protective neutralizing antibody response
[31]. In the present report, we show that rLCMV/INDG has
lost its pathogenic potential in mice but has retained the
property of LCMVwt to induce long-lived protective CTL
memory. Using newly developed techniques, we engineered
two additional recombinant LCM viruses to formally accredit
the attenuated phenotype of rLCMV/INDG to GP exchange
and to reproduce our ﬁndings with a second attenuated virus.
Our observations provide a strong rationale for testing
LCMV or other arenaviruses with foreign GPs as promising
live-attenuated vaccine candidates in nonhuman primate
models of arenaviral diseases.
Results
Attenuation of rLCMV/INDG Prevents Lethal Disease in
Infected Mice
Attenuated growth of rLCMV/INDG in cell culture [31, 36]
prompted us to study its ﬁtness and pathogenicity in infected
mice. We infected C57BL/6 mice intravenously (i.v.) with 2 3
10
4 PFU of the LCMVwt strain Armstrong (LCMV-ARM) or
with the same dose of rLCMV/INDG. Groups of mice were
killed 2, 4, and 8 d later to determine virus titers in spleen,
liver, kidney, brain, and blood (Figure 2A and 2B and
unpublished data). Following its typical kinetics [33], LCMV-
ARM replicated to initially high titers in spleen and liver but
was cleared to below detection limit within 6 to 8 d. In
contrast, rLCMV/INDG infectivity was undetectable in all
organs and at all time points tested. We therefore set out to
study the pathogenic potential of rLCMV/INDG. In mice, all
known LCMVwt strains including LCMV-ARM typically cause
lethal lymphocytic choriomeningitis (LCM) upon intracere-
bral (i.c.) inoculation. This immunopathologic disease is
mediated by virus-speciﬁc cytotoxic T cells, whereas the viral
infection per se is noncytolytic. Severe or fatal LCM is also a
frequent complication in accidental infection of human
adults [37]. Little is known about the capacity of different
LCMVwt isolates to cause central nervous system disease in
humans, but this potential side effect of live-attenuated
vaccines should be excluded as far as possible. We therefore
assessed the capacity of rLCMV/INDG to elicit lethal LCM
after i.c. inoculation of C57BL/6 mice (Figure 2C, Table 1).
Surprisingly, rLCMV/INDG-infected mice remained clinically
healthy during the entire period of observation, while LCMV-
ARM control infected mice exhibited signs of terminal LCM
within 6 d of infection. Notably, mice that are tolerant to
LCMV-GP due to transgenic expression of this protein in the
thymus (DEE mice [38]) developed normal LCM after i.c.
infection with LCMV-ARM (Table 1). Thus, the failure of
rLCMV/INDG to cause LCM was not due to the lack of the
LCMV-GP as one of the main targets of CTL-mediated
immunopathology. This indicated that GP exchange had
largely abrogated the virus’ pathogenic potential in mice.
Figure 2. Attenuation of rLCMV/INDG Prevents Lethal Disease in Infected
Mice
(A, B) C57BL/6 mice were infected i.v. with 2310
4 PFU of either rLCMV/
INDG or LCMV-ARM. At the indicated time points after inoculation,
groups of two or three mice were killed and viral titers in spleen (A) and
liver (B) were determined by immunofocus assay. Symbols represent
individual mice.
(C) C57BL/6 mice (four per group) were infected with 3310
3 PFU rLCMV/
INDG or LCMV-ARM i.c. At the time points indicated, they were
monitored for clinical signs of choriomeningitis. Animals with terminal
disease were killed according to the Swiss law for animal protection.
(D) Mice were infected with 3310
3 PFU rLCMV/INDG i.c. Ten days later,
NP396-specific CD8
þ T cells in peripheral blood were enumerated using
MHC class I tetramers. Numbers in the upper right quadrants indicate the
percentage of NP396-specific CD8
þ T cells within the total CD8
þ T cell
population. Each panel (A–D) shows the results from one representative
experiment of two similar ones.
DOI: 10.1371/journal.ppat.0020051.g002
Figure 1. Wild-Type and Recombinant Viruses Used in this Study
All LCM viruses used in this study contain an identical L segment
encoding for the LCMV RNA-dependent RNA polymerase (L ORF) and for
the matrix protein Z. All four viruses also encode for an identical NP
translation product. The three partially cDNA derived viruses (rLCMV/
INDG, rLCMV/NJG, and rLCMV-ARM*) carry, however, two noncoding
genetic tags in the NP ORF as indicated (*; see also Figures 4 and S6). The
LCMV-GP ORF of LCMV-ARM and rLCMV-ARM* is substituted for INDG
and NJG in rLCMV/INDG and rLCMV/NJG, respectively. Arrows indicate
the orientation of individual ORFs. Inverted writing (NP, L) indicates that
in the viral genome, the respective ORFs are encoded in antisense
polarity.
DOI: 10.1371/journal.ppat.0020051.g001
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Cell-Mediated Immunity against Lethal Challenge with
Wild-Type Virus
Infection with LCMVwt represents a paradigm for induc-
tion of life-long protective T cell memory [19], and we had
previously found that i.v. rLCMV/INDG infection evoked not
only a rapid and potent neutralizing antibody (nAb) response
but also high peak frequencies of viral epitope speciﬁc CD8
þ
T cells [31]. Here, we made analogous observations after i.c.
infection with rLCMV/INDG (Figure 2D). This was not
surprising considering that most of the i.c. inoculum is
rapidly drained to the systemic circulation [39]. To test
whether GP recombinant arenaviruses could be used as live-
attenuated vaccines, we determined the protective capacity
and longevity of T cell memory in rLCMV/INDG-immune
C57BL/6 mice. Lethal i.c. challenge with LCMV-ARM was
performed at various time points (Table 2). This setting ruled
out any contribution of serum antibodies to challenge virus
control because LCMV-ARM and rLCMV/INDG are exclu-
sively neutralized by either LCMV-GP1  or INDG-speciﬁc
antibodies, respectively ([31]; see also Table S1) and therefore
represent distinct serotypes. In three independent experi-
ments, a total of 21 of 24 animals immunized with 10
4 PFU of
rLCMV/INDG i.v. and all 16 mice immunized with 10
3 PFU of
rLCMV/INDG i.c. survived a lethal i.c. challenge with LCMV-
ARM at time points ranging from 30 to 321 d after
immunization (Table 2). This protective effect of rLCMV/
INDG immunization correlated with the rapid expansion of
virus-speciﬁc memory CTL and with efﬁcient clearance of
LCMV-ARM from the central nervous system before infection
became too widespread (for details, see Protocol S1 and
Figure S1). A lack of protection in a challenge experiment
carried out at days 345 and 386 suggested, however, that
protection might not last inﬁnitely.
In contrast to the needs in endemic areas (longevity of
protection), a vaccine for health care workers or military
personnel deployed to such places should primarily provide
rapid protection. The same criterion would also apply in case
of a bioterrorist attack. Thus, it was important to ﬁnd that
rLCMV/INDG immunization was protective even when
administered no earlier than 7 d prior to i.c. challenge with
LCMV-ARM and that protection was even seen in two of ﬁve
animals challenged on day 3 after immunization (Table 2).
rLCMV/INDG Immunization Confers Rapid and Long-Lived
Cell-Mediated Protection against Overwhelming Systemic
Infection and Liver Disease
To confer protection against arenaviral hemorrhagic
fevers, vaccine-induced cell-mediated immunity should pre-
vent overwhelming viremia, the primary predictor for the
outcome of human LFV infection [9]. Moreover, efﬁcient
virus control should avoid the disturbance of clinical
parameters predictive for an unfavorable outcome, among
them elevated serum aspartate aminotransferase (AST)
activity, which is used to monitor human LF [9]. In mice,
high-dose infection with the viscerotropic WE strain of
LCMV results in prolonged viremia, severe AST elevation,
and occasionally a fatal outcome [40, 41]. We therefore tested
whether immunization with rLCMV/INDG could protect mice
against high-dose LCMV-WE challenge. Considering the
similarly efﬁcient immune protection conferred by i.c. or
Table 1. The Viral GP Determines Pathogenicity of Engineered
LCM Viruses in i.c. Infected Mice
Experiment
a Mouse
Genotype
a
Virus
a Dose
(PFU) i.c.
a
Mice
Tested
b
Chorio-
meningitis
c
1 C57BL/6 LCMV-ARM 3 3 10
3 33
rLCMV-ARM* 3 3 10
3 33
rLCMV/INDG 3.3 3 10
3 30
rLCMV/NJG 3.8 3 10
3 50
2 C57BL/6 LCMV-ARM 3 3 10
3 33
DEE LCMV-ARM 3 3 10
3 44
aIn two separate experiments (1 and 2), mice of the indicated genotypes were infected i.c.
with the indicated viruses and dose.
bNumber of mice per group. The differential ability of rLCMV/INDG and LCMV-ARM to
cause disease was confirmed in at least three experiments (see also Figure 2C and Table
3). For rLCMV-ARM*, the results were corroborated in the experiment shown in Table 3.
cNumber of mice that developed terminal choriomeningitis and had to be killed
(according to the Swiss law for animal protection). Disease onset was on day 6, and the
remaining animals were observed for .30 d.
DOI: 10.1371/journal.ppat.0020051.t001
Table 2. Recombinant LCM Viruses Induce Rapid and Long-
Lasting Protection against Lethal Choriomeningitis
Immunization
a Time between
Immunization
and Challenge
(days)
b
Number of Mice
Protected/Number
of Mice Tested
c
Experiment
d
10
4 PFU rLCMV/
INDG i.v.
3 2/5 A
7 4/4 B
30 3/3 C
120 3/3 D
204 4/6 E
221 3/3 D
228 2/3 C
315 3/3 D
321 3/3 D
345 0/3 F
386 0/1 F
10
3 PFU rLCMV/
INDG i.c.
30 3/3 C
150 3/3 C
236 4/4 C
242 3/3 C
270 3/3 C
10
4 PFU rLCMV/
NJG i.v.
204 3/3 E
Without rLCMV
immunization
Not applicable 0/3 A
0/3 B
0/3 C
0/4 D
0/3 E
0/3 F
aC57BL/6 mice were immunized with the indicated doses of rLCMV/INDG or rLCMV/NJG
i.v. or i.c. as indicated. Controls were left without immunization. For simplicity, viral
immunization doses ranging from 10
4 to 3 3 10
4 PFU and from 10
3 to 3 3 10
3 PFU are
summarized as 10
4 PFU and 10
3 PFU, respectively.
bAt the indicated time point after immunization (days), mice were challenged i.c. with 33
10
3 PFU LCMV-ARM.
cNumber of mice that were protected against lethal choriomeningitis per total number of
mice tested.
dThis table summarizes the results from six individual experiments (A–F) as indicated.
DOI: 10.1371/journal.ppat.0020051.t002
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Live-Attenuated Arenavirus Vaccinesi.v. infection with rLCMV/INDG (Table 2), mice that had
originally been inoculated via either route were used likewise
for the subsequent sets of experiments. The peripheral CD8
þ
T cell pool of mice immunized 109 and 314 d previously by i.v.
or i.c. inoculation of rLCMV/INDG, respectively, contained
approximately 0.2% to 0.5% NP396-speciﬁc memory CTL
(Figure 3A). Upon high-dose (2 3 10
5 PFU) LCMV-WE i.v.
infection (sharing the NP396 epitope with rLCMV/INDG),
these cells expanded to approximately 10% by day 4 and to
approximately 30% to 50% by day 7 after challenge. In naı ¨ve
control animals, only approximately 1% to 2% NP396-
speciﬁc CD8
þ T cells were detected no earlier than 7 d after
challenge. At this time point, mice without immunization
exhibited high virus load in blood, spleen, and liver, whereas
the virus had been cleared to below detectable levels in 109-d
rLCMV/INDG i.v. immune animals (Figure 3B–3D). Even in
mice that had been infected with rLCMV/INDG i.c. 314 d prior
to challenge, virus load was either considerably reduced or
undetectable. This was reﬂected in serum AST and alanine
aminotransferase (ALT) levels of immune mice that remained
in the normal range, whereas the corresponding values of
nonimmune control mice reﬂected serious disease (Figure 3E
and 3F). Histopathologic analysis of the liver 7 d after
challenge infection documented clearance of viral antigen
at the cellular level and revealed considerably milder
mononuclear inﬁltrations in the liver of rLCMV/INDG-
immune mice (Figure S2). The reduction in hepatocellular
damage was also reﬂected in a lower histopathological
hepatitis score (Figure 3G [42]). In the i.c. challenge model
with LCMV-ARM (Table 2), we had found that rLCMV/INDG-
induced protection was rapidly established. Analogous ob-
servations were made when mice were challenged with a high
dose of LCMV-WE i.v. either 3 or 6 d after immunization (see
Protocol S1 and Figure S3). Taken together, these experi-
ments showed that rLCMV/INDG immunization provided
rapid and long-lived cell-mediated immunity against over-
whelming systemic infection and liver disease elicited by a
viscerotropic LCMV isolate.
A Second GP Exchange Virus Reproduces the Phenotype
of rLCMV/INDG
The high degree of attenuation of rLCMV/INDG combined
with its protective capacity suggested that GP exchange
represented a promising general strategy to attenuate
arenaviruses for use as live vaccines. It remained, however,
to be formally demonstrated that GP exchange was indeed
the main reason for the attenuated phenotype of rLCMV/
INDG. Randomly accumulated mutations in the virus’ RNA
genome could also have accounted for a loss of ﬁtness.
Moreover, the partial cDNA origin of rLCMV/INDG per se
could have caused some attenuation [43]. This prompted us to
determine whether the phenotype of rLCMV/INDG was
reproducible with another GP exchange virus. For this, we
generated a recombinant LCMV (rLCMV/NJG, Figure 1)
expressing the GP of the New Jersey (NJ) serotype of VSV
instead of INDG or LCMV-GP. rLCMV/INDG had so far
represented the only genetically engineered recombinant
arenavirus, and the protocol we had used for its generation
had been extremely labor intensive [36]. For the recovery of
rLCMV/NJG, we therefore developed a new experimental
protocol that was, like the original protocol, based on the
reassortment of viral genome segments (schematically de-
Figure 3. Efficient Control of High-Dose LCMV-WE Infection and
Prevention of Liver Disease by rLCMV/INDG-Induced Memory CTL
(A) C57BL/6 mice were infected with 2310
4 PFU rLCMV/INDG i.v. or with
3310
3 PFU rLCMV/INDG i.c. on day 109 and on day 314, respectively.
On day 0, the immunized mice and a group of naı ¨ve control mice
(‘‘none’’) were challenged with 2310
5 PFU LCMV-WE i.v. The frequency
of NP396-specific memory CD8
þ T cells in peripheral blood was assessed
prior to challenge (day 0) and on day 4 and day 7 after challenge using
MHC class I tetramers. The numbers in the upper right quadrants indicate
the frequency of NP396-specific CD8
þ T cells within the total CD8
þ T cell
population in peripheral blood and represent the mean 6 SD of three or
four mice per group and time point.
(B–D) All mice were killed 7 d after challenge, and viral titers in liver,
spleen, and blood were determined by immunofocus assay.
(E, F) On day 7, serum AST and ALT levels were determined.
(G) Liver sections were scored for hepatitis. The symbols in B–G represent
individual mice. Statistical analysis was carried out for E–G. Significant
differences between groups are indicated for **P , 0.01. All findings
described were reproduced in the experiment shown in Figure S5.
DOI: 10.1371/journal.ppat.0020051.g003
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Live-Attenuated Arenavirus Vaccinespicted in Figure 4A). We transfected BHK-21 cells with a
polymerase I (pol-I) driven vector [pSNJ( ), Figure 4B] for
intracellular expression of an NJG recombinant LCMV S
segment RNA in combination with polymerase II (pol-II)-
driven plasmids for coexpression of the minimal viral trans-
acting factors NP and L (pC-NP, pC-L [2, 36]). Forty-eight
hours later when recombinant S segment ribonucleoproteins
had formed intracellularly [36], the transfected cells were
infected with rLCMV/INDG helper virus, providing an L
genomesegmentforreassortment.TheappearanceofrLCMV/
NJG reassortant virus in the supernatant and the subsequent
selection process were monitored by immunoﬂuorescence.
For this, fresh BHK-21 cells were incubated with culture
supernatant sampled at different time points, and the rLCMV/
INDG- or rLCMV/NJG-speciﬁc infectivity contained therein
wasdetected24hlaterinasemiquantitative mannerbyINDG-
or NJG-speciﬁc immunoﬂuorescence staining (Figure 4C).
Supernatant collected 24 h after helper virus infection
contained already a low but detectable fraction of rLCMV/
NJG reassortant virus (Figure 4C, P0/24h). To select against the
dominant population of rLCMV/INDG helper virus, the mixed
virus population was propagated for two consecutive passages
(P1 and P2 in Figure 4A and 4C) on fresh BHK-21 cells in the
presence of INDG-neutralizing monoclonal antibody (VI-7
[31]). This procedure resulted in a substantial enrichment of
rLCMV/NJG and simultaneously in the loss of rLCMV/INDG to
below detectable levels by immunoﬂuorescence. The so-
obtained population of rLCMV/NJG was subject to a single
round of limiting dilution, and the absence of rLCMV/INDG
helper virus in rLCMV/NJG (,1 PFU in 10
4 PFU of rLCMV/
NJG) was veriﬁed by RT-PCR (Figure 4D).
Characterization of rLCMV/NJG in cell culture (Table S1)
showed that this virus was neutralized by VSV-NJ speciﬁc,
but not by VSV-IND  or LCMV-ARM speciﬁc, monoclonal
antibodies (mAbs), demonstrating that receptor binding and
cell fusion of rLCMV/NJG were mediated by the foreign NJG
protein as expected. Moreover, we observed that rLCMV/NJG
infection elicited a very rapid and potent serotype-speciﬁc
nAb response (Protocol S1 and Figure S4) as previously
reported for rLCMV/INDG [31]. Most important, however,
rLCMV/NJG and rLCMV/INDG exhibited similarly attenuated
growth in cell culture when compared to LCMV-ARM (Figure
5A). In accordance with this, rLCMV/NJG failed to induce
clinically apparent disease in i.c. infected mice as previously
observed with rLCMV/INDG (Table 1). In further analogy, a
single i.v. immunization with rLCMV/NJG protected against
lethal i.c. challenge with LCMV-ARM (Table 2) or conferred
long-lived CTL memory and resistance against high-dose i.v.
challenge with LCMV-WE (Figure S5, compare to Figure 3).
Wild-Type Pathogenicity of an Engineered LCM Virus
Expressing LCMV-GP
Next, we addressed the possibility that the attenuation of
rLCMV/INDG and of rLCMV/NJG was due to their partial
origin from cDNA [43] or that it was a result of randomly
accumulated mutations in the large genome segment. We
therefore substituted the recombinant S segment in rLCMV/
INDG for a cDNA-derived and genetically tagged S segment
encoding for wild-type LCMV-GP (Figures 1A and S6). The
new virus, named rLCMV-ARM*, was recovered by the same
strategy as described for rLCMV/NJG (Figure 4A). Additional
technical details and a genetic characterization of rLCMV-
Figure 4. Generation and Characterization of rLCMV/NJG
(A) Schematic describing the protocol for generation of rLCMV/NJG.
(B) pSNJ( ) was designed analogous to pSIND (also referred to as pSr( )
[36]). It expresses in genomic ( ) polarity a recombinant LCMV S segment
where the LCMV-GP ORF was substituted for the NJG gene. Transcription
is driven by the murine polymerase I promotor (PIP) and is terminated
upstream of the murine polymerase I terminator (PIT). UTR, untranslated
region; IGR, intergenic region; *noncoding single nucleotide tags.
(C) BHK-21 cells on duplicate coverslips were infected for 24 h with
supernatants collected from the experiment outlined in A. Staining with
INDG- or NJG-specific mAbs as indicated provided a rough estimate of
the relative proportions of rLCMV/INDG and rLCMV/NJG contained in the
supernatants tested.
(D) BHK-21 cells (10
6 per M6 tissue culture well) were infected with
different doses of rLCMV/INDG or of rLCMV/NJG or with both viruses in
different combinations as indicated in the chart. At 48 h later, the cells as
well as the supernatant were collected. Total cellular RNA was extracted
and was processed for detection of INDG and NJG RNA by RT-PCR. The
PCR products were separated by agarose gel electrophoresis and were
visualized by ethidium bromide staining. Specific amplification products
of the expected size are indicated with arrows. Viral infectivity in the
supernatant (SN) was measured by immunofocus assay [PFU/ml SN (w/o
nAb) listed in the chart under the gel picture]. In addition, an aliquot of
supernatant was incubated with VSV-NJ neutralizing mAb H6B9D5 prior
to testing the remaining infectivity [see PFU/ml SN (þVSV-NJ nAb)] to
discriminate rLCMV/INDG from rLCMV/NJG infectivity.
DOI: 10.1371/journal.ppat.0020051.g004
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ARM* was neutralized by the same mAbs and hyperimmune
sera as wild-type LCMV-ARM (Table S1) and, even more
important, propagation of rLCMV-ARM* in cell culture was
indistinguishable from LCMV-ARM (Figure 5B). To deter-
mine the ﬁtness of rLCMV-ARM* in vivo, we infected mice
i.v. with 10
5 PFU of either rLCMV-ARM* or LCMV-ARM and
determined viral titers in the spleen 3, 6, and 9 d later (Figure
5C). Virus load and the kinetics of clearance were identical in
both groups. In accordance with this, the CD8
þ T cell
responses elicited by the two viruses were indistinguishable
(Protocol S1 and Figure S7). As the most stringent test for
pathogenicity, we performed i.c. inoculation experiments.
Infection of C57BL/6 mice with 3 3 10
3 or even with only 3
PFU of rLCMV-ARM* was invariably lethal (Tables 1 and 3),
demonstrating that rLCMV-ARM* behaved like wild-type
LCMV-ARM. Thus, the attenuation of rLCMV/INDG and of
rLCMV/NJG was due to GP exchange and could not be
attributed to their partial origin from cDNA or to accumu-
lated mutations in their L genome segment.
No Detectable Gain in rLCMV/INDG Pathogenicity after
Propagation in Immunodeficient Hosts
A major concern and a common drawback of live-
attenuated viral vaccines lie in their potential for reversion
[44]. In particular, viral variants of increased ﬁtness and
pathogenicity may be selected during persistent infection of
immunocompromized vaccinees that continue to shed virus
[45]. We therefore assessed how easily rLCMV/INDG could
evolve into a virus that was pathogenic for mice. For this, we
infected ﬁve either interferon type I receptor
 /  RAG
 / 
double deﬁcient mice (AR) or interferon type I receptor
 / 
interferon type II receptor
 /  RAG
 /  triple deﬁcient mice
(AGR [46]) with rLCMV/INDG and kept them in three
Table 3. No Detectable Gain in rLCMV/INDG Pathogenicity after Propagation in Immunodeficient Hosts
Virus
a Host
Genotype
b
Persistent
Infection
c
Tissue Culture
Passage
d
Infectivity of i.c.
Inoculum (PFU)
e
Number of Mice with
Choriomeningitis/
Number of Mice Tested
f
Percent H-2D
bNP396
þ of
CD8
þ (Mean 6 SD)
g
rLCMV/INDG AGR 265 d 0 36 0/3 9.6 6 5.3
rLCMV/INDG AR 250 d 1 5 0/3 8.5 6 1.8
rLCMV/INDG AR 225 d 1 27 0/3 3.9 6 1.7
rLCMV/INDG AR 225 d 1 36 0/3 9.0 6 3.0
rLCMV/INDG AR 300 d 1 8 0/3 2.0 6 0.5
rLCMV-ARM* Not applicable;
laboratory stock virus
Multiple 3 6/6 Not measured; killed on day 7
due to terminal disease
rLCMV/INDG Not applicable;
laboratory stock virus
Multiple 3 3 10
3 0/3 3.8 6 2.0
aViral preparations as indicated were inoculated i.c. into C57BL/6 mice. Two independent experiments are summarized: Viremic serum was administered simultaneously with the
experimental groups reported in Table 1 (serving as positive controls) to prevent loss of infectivity due to repeated freezing and thawing. The remaining groups represent an individual
experiment.
bAR and AGR mice were infected with rLCMV/INDG to serve as highly permissive hosts. Each mouse was housed in a separate cage except for virus donors from days 225 and 250.
cAfter the indicated period of time, blood of individual AR and AGR mice was collected.
dViremic serum of the AGR mouse was used directly for the experiment (0 cell culture passages). The rLCMV/INDG populations in the blood of AR mice were propagated once on BHK-21
cells (1 cell culture passage).
eViral infectivity in the i.c. inoculum (30 ll of undiluted viremic serum or 30 ll of undiluted tissue culture supernatant) as determined by tissue culture immunofocus assay. Viral laboratory
stocks of rLCMV/INDG and rLCMV-ARM* were diluted to yield an inoculation dose as indicated.
fThe indicated numbers of C57BL/6 mice were inoculated i.c. and were monitored twice daily for signs of terminal choriomeningitis. Diseased mice were killed in accordance with the Swiss
law for animal protection. Onset of choriomeningitis in rLCMV-ARM*–infected mice was on day 7. Observation period for the remaining groups: .30 d.
gThe frequency of NP396-specific cells among CD8
þ T cells in blood was measured on day 8 (group inoculated with viremic serum of AGR mouse) or on day 10 (other groups) after
infection by MHC class I tetramers to verify infection had occurred. Two or three naı ¨ve control mice were tested per experiment and exhibited background levels of   0.12%. Mice
inoculated with rLCMV-ARM* exhibited terminal choriomeningitis, requiring them to be killed prior to the measurements.
DOI: 10.1371/journal.ppat.0020051.t003
Figure 5. Attenuated Propagation of rLCMV/NJG but Not of rLCMV-
ARM*
(A) BHK-21 cells (10
6 per M6 well) were infected with the indicated
viruses at a multiplicity of infection of 0.01, and infectious virus in the
supernatant was measured at the indicated time points. Symbols
indicate the mean of three tissue culture wells (SD bars project into
the symbol size).
(B) BHK-21 cells in M6 tissue culture wells were infected with LCMV-ARM
or rLCMV-ARM* at multiplicity of infection of 0.01, and infectious virus in
the supernatant was measured at the indicated time points. The symbols
represent values from a single cell culture well. One representative
experiment of two is shown.
(C) C57BL/6 mice infected i.v. with 10
5 PFU LCMV-ARM or rLCMV-ARM*
were killed at the indicated time points, and virus titers in spleen were
measured. Symbols represent individual mice. Analogous results were
obtained from liver tissue (not shown). One representative experiment of
two is shown.
DOI: 10.1371/journal.ppat.0020051.g005
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transmission between mice. The combined genetic deﬁcien-
cies of these animals allowed rLCMV/INDG to readily
establish viremia and to replicate systemically (AB, DM, and
DDP, unpublished data), which should facilitate the evolution
of the viral quasi-species and the emergence of more
pathogenic variants [47]. Notably, rLCMV/INDG viremia in
these mice did not cause clinically apparent disease,
conﬁrming our earlier observation that this virus is non-
cytolytic in vivo [36], which may be of importance with regard
to vaccine safety. To test for a clear increase in viral
pathogenicity after 225 to 300 d of in vivo replication, we
inoculated C57BL/6 mice i.c. with viremic serum or with
undiluted supernatant from a single cell culture passage of
blood-derived virus (Table 3). Mouse-passaged rLCMV/INDG
preparations contained no more than approximately 10
2 to
10
3 PFU/ml infectious virus due to low level viremia even in
AGR mice and relatively poor in vitro ampliﬁcation of ex vivo
isolated rLCMV/INDG (unpublished data). Accordingly, the
i.c. inoculum that could be administered to C57BL/6
indicator mice was relatively low (,50 PFU in 30 ll, see
Table 3). Still, all viral preparations tested elicited high
frequencies of epitope-speciﬁc CD8
þ T cells indicative for a
productive infection, but the infected animals remained
clinically healthy. This failure of mouse-passaged rLCMV/
INDG to induce disease could unlikely be attributed solely to
dose limitations but suggested stable attenuation. Even an i.c.
inoculum of a single PFU of LCMV-ARM is lethal in mice [41],
and analogous ﬁndings were made here with an i.c. inoculum
of only 3 PFU of rLCMV-ARM* (Table 3). Furthermore, the
ﬁnding that only low amounts of virus were recovered from
the serum of AR and AGR mice provided per se additional
support for this notion. Nevertheless, additional testing will
be needed to conﬁrm and extend these ﬁndings, and a certain
increase in ﬁtness concomitant with prolonged or even
repeated in vivo passage of rLCMV/INDG seems likely and
cannot be excluded at present [47]. Similarly, limitations in
the volume and hence in the amount of infectivity that could
be administered i.c. have so far precluded the formal
assessment of a 50% lethal dose (LD50) for rLCMV/INDG,
rLCMV/NJG, or any of the ex vivo isolated virus populations
shown in Table 3. Considering, however, that even the
administration of low doses (1 to 10 PFU) of rLCMV/INDG
elicited considerable frequencies of antiviral CTL, whereas
i.c. infections with up to 10
4 PFU of rLCMV/INDG failed to
elicit clinical disease (Figure 2C and Tables 1 and 3, and
unpublished data), the safety margin for such a vaccine is
likely to be broad, i.e.,  100-fold the dose needed for
vaccination. Even arenaviruses with foreign GPs are, however,
unlikely to be considered for application in pregnant women
or in newborns, owing to the teratogenic potential of their
parent viruses. Also, we had previously reported that rLCMV/
INDG persists in neonates, and it was therefore of concern
that the virus might also persist in the central nervous system
when administered in adult life. rLCMV/INDG was detectable
in the meninges by immunohistochemistry around 4 d after
i.c. inoculation of adult mice although at lower levels than
LCMVwt. Yet, the virus was cleared to below detection levels
of our RT-PCR assay within 2 wk, whereas it persisted in
neonatally infected animals (Figure S8 and unpublished data).
Also, upon i.v. infection, viral RNA in the serum was
detectable by RT-PCR on only day 4 but not on day 8
(unpublished data), alleviating potential concerns regarding
the virus’ ability to establish a persistent infection in adult
immunocompetent individuals. It is clear, however, that
arenaviruses with foreign GPs need to be investigated in
much more detail, speciﬁcally also in nonhuman primate
models, before projections on their use in the human
population can be made.
Discussion
The directed introduction of mutations in viral genes often
results in a complete loss of function [48], abrogating the
virus’ viability and thereby also its immunogenicity. Con-
versely, even RNA viruses carrying multiple attenuating point
mutations are prone to reversion [44]. Hence, the deletion of
a dispensable nonstructural gene [49] or the substitution of a
structural gene for a foreign protein like in the present
report may provide an advantageous new strategy. Arenavi-
ruses have only four known genes and hence the range of
potential targets is limited. As supported by recent muta-
genesis studies, major changes in the minimal viral trans-
acting factors NP or L would unlikely be tolerated [48]. Z
mutants with residual budding activity have been character-
ized [2], and therefore the viral matrix protein may represent
an attractive target for attenuating mutagenesis. Yet, the
concerns related to the possibility of back mutation and
phenotypic reversion would remain. In this respect, exchange
of the arenavirus GP for foreign surface determinants like
VSVG may be entirely different because the roles of LCMV-
GP in the viral life cycle are multifaceted. Recent studies have
shown that the signal peptide of LCMV-GP serves not only to
target the nascent GPC polypeptide to the endoplasmic
reticulum: It is apparently needed at multiple steps of GP
biosynthesis and trafﬁcking as well as for its functioning in
the viral envelope [27–29]. More important, the signal
peptide is efﬁciently packaged in viral particles and is
thought to contribute to the budding process by supporting
membrane curvature [27]. Highly speciﬁc functions are also
located in the C-terminus of arenavirus GPs. A cluster of
basic amino acid residues in the intracellular portion of
LCMV-GP is supposed to mediate critical protein-protein
interactions [30]. Such interplay includes with all likelihood
the binding of GP to intracellular viral components and
thereby either directly or indirectly with the ribonucleopro-
tein [50], allowing for the efﬁcient recruitment of GP
molecules into viral particles. The INDG or NJG proteins of
the engineered viruses can apparently mediate receptor
binding and cell fusion, whereas additional roles of LCMV-
GP including those mentioned above are likely to remain
without substitute. To recover these functions of LCMV-GP
in the virus’ life cycle, a foreign GP like INDG or NJG would
need to undergo a major evolution, including de novo
development of functional domains, e.g., those in the GP
signal peptide and C-terminal portion but probably many
more. These deﬁciencies may therefore provide the molec-
ular basis for the relatively stable, attenuated phenotype
observed in this study. Alternatively and not mutually
exclusively, INDG- or NJG-mediated cell tropism in the
infected central nervous system or the reported differences in
the humoral and cellular immune response ([31], see also
Figure S4) or both could account for the lack of disease in
rLCMV/INDG or rLCMV/NJG i.c. infected mice. Preliminary
results support, however, the notion that the cell tropism of
LCMV-ARM and of rLCMV/INDG in the acutely infected
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unpublished data). It rather appears that a lower viral burden
in the rLCMV/INDG-infected central nervous system shifts
virus-host balance in favor of the rLCMV/INDG-infected host
(similarly to LCMV-ARM infection in immune mice, see
Figure S1). Although control of rLCMV/INDG and rLCMV/
NJG is unaffected in B cell–deﬁcient mice ([31] and AB and
DDP, unpublished data), the rapid and strong induction of
nAbs (Figure S4) is likely to contribute to the efﬁcient
elimination of these viruses. Increased susceptibility to the
host’s innate immune defense represents an alternative and
not mutually exclusive explanation that is currently under
investigation (AB, DM, and DDP, unpublished data).
A number of recombinant vector systems have been
developed as potential LFV vaccines ([14–18], see introduc-
tion section). The attenuated Junin virus variant Candid #1 is,
however, the only arenavirus vaccine ever in clinical use. It
has successfully been administered to agricultural workers at
immediate risk of contracting Junin virus, the causative agent
of Argentine hemorrhagic fever [25]. Concerns about its
phenotypic stability and safety [26] render it, however,
inappropriate for mass vaccinations. Accordingly, strategies
like recombinant vector systems and DNA vaccination may be
the methods of choice to protect entire populations at only
low risk or at unpredictable risk (e.g., bioterrorist attacks),
because these vaccination protocols can be tuned for an
optimal safety proﬁle. In highly affected populations (see
above), efﬁcacy and safety may be balanced differently.
Moreover, logistic constraints in Third World countries
where LFV and other arenaviruses are endemic will not
allow for regular booster immunizations. Under such
conditions, not only the efﬁcacy but also the longevity of
vaccine protection becomes a primary criterion that is
commonly best fulﬁlled by live-attenuated vaccines. Hence
the development of recombinant vaccine vectors but also of
live-attenuated vaccines should be pursued both in parallel
and as complementary strategies for different needs in
different areas of the world.
For arenavirus family members other than LCMV, genet-
ically engineered infectious viruses have not been reported so
far. The approach outlined here and in recent work [36, 51,
52] should be applicable to all other arenaviruses including
the high-risk pathogens. Thereby, attenuated viruses could be
tailored for the purpose of vaccination and, if needed, could
be adapted upon testing in animal models including nonhu-
man primates. This should allow for the rationale optimiza-
tion of an LFV vaccine strain to be used in endemic areas or
in cases of imminent bioterrorist attacks. Based on the well-
established phenomenon of heterologous cell-mediated im-
munity between different Old World arenaviruses ([16, 20,
22–24], see introduction section), rLCMV/INDG and rLCMV/
NJG themselves should also be considered for testing as LFV
vaccines. Cell-mediated immunity to the viral NP is protective
in the guinea pig model and, at a challenge dose of 10
3 PFU,
protection was also observed in nonhuman primates [16].
This is a likely dose scenario for accidental exposure to
persistently infected Mastomys urine (;10
3 PFU/ml [53]).
When a challenge dose of 10
4 PFU was given to primates,
LFV-GP–speciﬁc T cell immunity seemed of superior
protective capacity [16]. These differences may be due to
epitope dominance in the speciﬁc monkeys tested, something
that is primarily related to the individual’s MHC haplotype
and less to the species [54]. In support of this notion, studies
on human CD4
þ T cell immunity to LFV have documented
strong NP, as well as GP, reactivity, and epitope-speciﬁc
responses were found to correlate with the individual’s MHC
haplotype [55, 56]. Moreover, immune responses to subdo-
minant viral epitopes can also be protective [57]. Thus,
arenaviruses with foreign GPs inducing potent cell-mediated
immunity against NP, but not GP, and depending on the
haplotype, potentially also against Z and L, should in
principle have the capacity to protect. In any case, however,
GP-speciﬁc immunity [23] would be beneﬁcial, also with
regard to a potential additive effect of GP-speciﬁc neutraliz-
ing antibodies [11]. As an alternative attractive possibility,
rLCMV/INDG or rLCMV/NJG or both in a sequential order
(see later) could therefore be used to prevent potential side
effects of a subsequent immunization with wild-type arena-
viruses like LCMV, MV, or reassortants that are known to
confer efﬁcient long-term protection against LF [16, 20–22].
An analogous approach has recently been put forward in a
study for smallpox vaccination [58].
Similar to LCMV-WE infection of mice ([40], compare to
Figures 3, S2, S3, and S5), a human LFV vaccine should limit
systemic virus spread at an early stage [9, 59]. As a further
analogy to LCMV infection of mice [36], LFV in humans and
nonhuman primates seems primarily controlled by cellular
[12, 13, 22] rather than humoral [9, 11, 12] immunity, and
hence a vaccine should induce long-lived memory CTLs. We
cannot exclude, however, that mechanisms of viral interfer-
ence, either directly or via the activation of innate immunity
[60, 61], may have contributed to the protective effects
observed very early after vaccination, i.e., on day 3 (compare
Table 2 and Figure S3). The mechanisms underlying the
ability of rLCMV/INDG and rLCMV/NJG to elicit long-lived
cell-mediated immunity have not yet been elucidated. It
seems likely, though, that their noncytolytic behavior
facilitates prolonged antigen presentation by infected den-
dritic cells, similar to the human yellow fever vaccine [62].
Still, immune protection could likely be optimized by prime-
boost regimens. After immunization with an engineered virus
like rLCMV/INDG, however, the induction of nAbs to the
respective GP ([31], Figure S4) would likely interfere with
efﬁcient boosting. The sequential application of different
serotypes like rLCMV/INDG and rLCMV/NJG should circum-
vent this problem, and VSV-GPs offer excellent tools for this
purpose, also because the vast majority of the human
population lacks preexisting humoral immunity to VSV. In
rural areas where logistical constraints represent a major
limitation, recombinant expression of a viral GP from an
unrelated human pathogen would offer the additional
advantage of simultaneously protecting not only against
arenaviral disease but also against an unrelated third party
virus with similar distribution (e.g., LFV and yellow fever
virus in the case of West Africa [12, 13]).
Taken together, the experiments presented herein demon-
strate that the reverse genetic engineering of stably attenu-
ated live arenavirus vaccines is feasible. They show also that
abrogation of arenaviral pathogenicity does not necessarily
go along with a reduction of immunogenicity to below a
critical threshold needed for protective immunity. The
identiﬁcation of the GP as an Achilles’ heel of arenaviruses
offers an attractive strategy, and together with the techno-
logical advances presented here and elsewhere [36, 51, 52]
may provide a basis for the engineering of live-attenuated
vaccine strains. We hope that this may pave the way to the
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orrhagic fevers that every year affect hundreds of thousands
in West Africa and become increasingly distributed over the
entire globe [7, 8].
Materials and Methods
Mice and animal experiments. C57BL/6 mice, interferon type I
receptor
 / RAG
 / double deﬁcient mice, interferon type I receptor
 /
  interferon type II receptor
 /  RAG
 /  triple deﬁcient mice [46], and
DEE mice [38] were bred at the Institut fu ¨r Labortierkunde,
University of Zurich, Zurich, Switzerland, and were housed under
SPF conditions for the experiments. The i.c. infected mice exhibiting
signs of terminal choriomeningitis (shaky walk, trembling, convul-
sions) were killed according to the Swiss law for animal protection.
Mice infected with LCMV-ARM or rLCMV-ARM* were monitored
twice daily during the critical period. All animal experiments were
carried out with authorization of the Veterina ¨ramt of the Kanton
Zu ¨rich and in accordance with the Swiss law.
Enumeration of epitope-speciﬁc CD8
þ T cells. Epitope-speciﬁc
CD8
þ T cells were stained with APC- or PE-conjugated MHC class I
tetramers containing the immunodominant H-2D
b restricted LCMV
epitopesNP396–404(NP396)orGP33–41(GP33)aspreviouslydescribed
[31]. Costaining was performed with anti–CD8a-FITC or anti–CD8a-PE
conjugate (clone 53–6.7) and with anti–B220-PerCPconjugate obtained
from BD PharMingen (San Diego, California, United States). The cells
were measured on a FACScalibur (Becton Dickinson, San Diego,
California, United States), and the frequency of tetramer
þCD8
þ cells
was calculatedaspercentage of the CD8
þB220
– lymphocyte population.
All FACS plots shown are gated on B220
 lymphocytes.
Viruses and virus titration. LCMV Armstrong ARM5.3b (LCMV-
ARM) is a triple plaque puriﬁed isolate of ARM CA 1371 obtained
originally from M. J. Buchmeier (The Scripps Research Institute, La
Jolla, California, United States). LCMV-WE was originally obtained
from F. Lehmann-Grube (Heinrich-Pette Institut, Hamburg, Ger-
many). Generation of rLCMV/INDG has been described [36]. VSV
serotype Indiana (VSV-IND) and VSV-NJ were originally obtained
from D. Kolakofsky (University of Geneva, Geneva, Switzerland).
LCMV-WE was propagated on L-929 cells. All other viruses were
grown on BHK-21 cells. LCMV and recombinants were titrated by
immunofocus assay on MC57 cells as previously described [31].
Statistical analysis. For the assessment of between-group differ-
ences in experiments with more than two groups, we performed one-
way ANOVA followed by multiple t-test (with Bonferroni adjustment
for multiple comparison) if the F-test of ANOVA indicated statisti-
cally signiﬁcant differences. Student’s t-test was used for experiments
with only two groups. The analysis was carried out using GraphPad
Prism software (Version 4.0b; GraphPad Software, San Diego,
California). P-values ,0.05 were considered statistically signiﬁcant
(*), P-values ,0.01 were considered highly signiﬁcant (**), and they
are indicated in the ﬁgures accordingly (* or **).
Histopathological scoring. Animals were lethally anesthetized with
pentobarbital and were transcardially perfused with saline followed
by 4% para-formaldehyde (pH 7.4). The liver was dissected and
postﬁxed overnight in fresh ﬁxative followed by parafﬁn embedding.
Histological evaluation was performed on 3-lm-thick sections stained
with hematoxylin-eosin (H-E). Hepatitis was scored from 0 (healthy
naı ¨ve controls) to a cumulative maximal score of 18 points according
to established criteria [42]. In brief, this necroinﬂammatory score
considers portal, periportal, and intra-acinar inﬂammatory cell
inﬁltration as well as various forms of liver cell damage and necrosis:
spotty (focal) lytic necrosis and apoptosis with liver cell drop-out,
piecemeal necrosis (interface hepatitis), simple conﬂuent necrosis
(death of groups of adjacent hepatocytes without clear zonal location
or bridging), zonal conﬂuent necrosis (zone 3), bridging necrosis
linking vascular structures, and panacinar or multiacinar necrosis.
For each animal, at least ten high-power ﬁelds were analyzed.
Supporting Information
Figure S1. Rapid Elimination of Intracerebral LCMV-ARM Infection
by rLCMV/INDG-Induced Memory CTL
(A) C57BL/6 mice were infected with 3 3 10
3 PFU rLCMV/INDG i.c.
on day  264. On day 0, the immunized mice and a group of naı ¨ve
control mice (‘‘none’’) were challenged with 3310
3 PFU LCMV-ARM
i.c. The frequency of NP396-speciﬁc memory CD8
þ T cells in
peripheral blood was assessed prior to challenge (day 0) and 4 d
after challenge using MHC class I tetramers. The numbers in the
upper right quadrants indicate the frequency of NP396-speciﬁc CD8
þ
T cells within the total CD8
þ T cell population in peripheral blood
and represent the mean 6 SD of three or four mice per group and
time point.
(B) All mice were killed 5 d after challenge, and viral titers in brain
and spleen were determined by immunofocus assay. Symbols indicate
individual mice.
Found at DOI: 10.1371/journal.ppat.0020051.sg001 (405 KB EPS).
Figure S2. Efﬁcient Clearance of LCMV-WE and Blunted Liver
Disease in rLCMV/INDG-Immune Mice
C57BL/6 mice were infected with 2 3 10
4 PFU rLCMV/INDG i.v. or
with 3 3 10
3 PFU rLCMV/INDG i.c. on day  109 and day  314,
respectively. On day 0, the immunized mice and a group of previously
naı ¨ve control mice (‘‘no immunization’’) were challenged with 2310
5
PFU LCMV-WE i.v. (same animals as in Figure 3). Seven days later, the
mice were killed, and either liver tissue was stained with H-E (left
column) or immunoﬂuorescent costaining was performed (right
column) to simultaneously detect LCMV antigen (green), CD3
þT cells
(red), and cell nuclei (DAPI, blue). Liver tissue samples of three mice
per group were analyzed, except for the group without challenge
consisting of two naı ¨ve mice (negative control). The pictures shown
were taken from areas with a representative degree of inﬂammation
and with representative amounts of viral antigen. The hepatitis score
for the same samples is shown in Figure 4G. An analogous
histopathological picture was also seen in tissue sections collected
in the experiment described in Figure S5 (not shown).
Found at DOI: 10.1371/journal.ppat.0020051.sg002 (11 MB EPS).
Figure S3. rLCMV/INDG-Induced Immune Protection Is Rapidly
Established
In two separate experiments shown in A–E and F–J, respectively,
C57BL/6 mice were either left untreated or immunized with 2 3 10
4
PFU rLCMV/INDG i.v. prior to challenge with LCMV-WE (2 3 10
5
PFU i.v.). The immunization was performed either 6 d (A–E) or 3 d
(F–J) prior to challenge. Eight days after challenge, the mice were
killed and virus titers were determined in blood (A and F), spleen (B
and G), and liver (C and H). In addition, AST (D and I) and ALT (E
and J) activity was determined in the serum. The symbols represent
individual mice. For each experiment (A–E and F–J), one representa-
tive of two is shown. Statistical analysis was carried out for D, E, I, and
J, and signiﬁcant differences between groups are indicated as *P ,
0.05 or **P , 0.01.
Found at DOI: 10.1371/journal.ppat.0020051.sg003 (402 KB EPS).
Figure S4. Rapid and Potent nAb Response to rLCMV/NJG Infection
C57BL/6 mice were infected i.v. with 2 3 10
4 PFU of rLCMV/INDG,
rLCMV/NJG, VSV-IND, or VSV-NJ. Serum was collected at the
indicated time points and was prediluted 40-fold for testing in plaque
reduction assays. Neutralizing IgM (A and C) and IgG (B and D)
against VSV-NJ (A and B) and against VSV-IND (C and D),
respectively, were measured as outlined in the chart. Symbols
represent the mean 6 SD of three mice.
Found at DOI: 10.1371/journal.ppat.0020051.sg004 (389 KB EPS).
Figure S5. Efﬁcient CTL Recall Response, Control of High-Dose
LCMV-WE Infection, and Prevention of Liver Disease in rLCMV/
INDG- or rLCMV/NJG-Immune Mice
(A) C57BL/6 mice were infected with 3 3 10
3 PFU rLCMV/INDG or
rLCMV/NJG i.c. on day  156. On day 0, the immunized mice and a
group of naı ¨ve control mice (‘‘none’’) were challenged with 2 3 10
5
PFU LCMV-WE i.v. The frequency of NP396-speciﬁc memory CD8
þT
cells in peripheral blood was assessed prior to challenge (day 0), on
day 4, and on day 7 after challenge using MHC class I tetramers. The
numbers in the upper right quadrants indicate the frequency of
NP396-speciﬁc CD8
þ T cells within the total CD8
þ T cell population
in peripheral blood and represent the mean 6 SD of three to ﬁve
mice per group and time point.
(B–D) All mice were killed 7 d after challenge, and virus titers in liver,
spleen, and blood were determined by immunofocus assay. Three
additional naı ¨ve mice without LCMV-WE challenge infection were
included as negative controls for the assay.
(E and F) On day 7, serum AST and ALT levels were determined. Four
naı ¨ve mouse sera were tested in parallel and are shown for
comparison.
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Sections were stained with H-E, and the severity of hepatitis was
scored. The symbols in (B–G) represent individual mice. Statistical
analysis was carried out for (E–G). Signiﬁcant differences between
groups are indicated as for *P , 0.05 or **P , 0.01.
Found at DOI: 10.1371/journal.ppat.0020051.sg005 (594 KB EPS).
Figure S6. Generation and Molecular Characterization of rLCMV-
ARM*
(A) Schematic describing the protocol for generation of rLCMV-
ARM*.
(B): pS*( ) was designed analogous to pSIND (also referred to as pSr( )
[36]). It expresses in genomic ( ) polarity a wild-type LCMV S segment
with two noncoding single nucleotide tags (*). Transcription is driven
by the murine polymerase I promotor (PIP) and is terminated
upstream of the murine polymerase I terminator (PIT). UTR,
untranslated region; IGR, intergenic region.
(C and D) Genetic tags introduced at position 819 and 1467 of the NP
ORF (with respect to the adenine in the start codon of the NP ORF as
nucleotide 1) convert single C residues of the LCMV-ARM NP cDNA
to T as in LCMV-WE without affecting the viral translation product.
RT-PCR products with gene speciﬁc primers NP2743r plus NP2223f
or Sseq5 plus Sseq2 span the respective tags allowing differentiation
of wild-type and cDNA derived viral genomes by digestion with EcoNI
and BbsI, respectively. Note that rLCMV/INDG should not yield an
RT-PCR product with the Sseq5/Sseq2 primer pair due to the lack of
binding of primer Sseq2 in the LCMV-GP ORF (C). Primers GP759r
and GP247 detect the LCMV-GP ORF by RT-PCR. VSVGPf and
VSVGPr primers amplify a fragment of INDG cDNA (not shown in
the schematic).
(D) Total cellular RNA was collected from BHK-21 cells that had been
infected with the indicated viruses for 48 h at a multiplicity of
infection of 0.1. The different primer pairs were used to detect
speciﬁc viral sequences as outlined in (C). All PCRs were carried out
with (þRT) or without ( -RT) RT of the template to rule out the
possibility that residual plasmid contaminations in rLCMV-ARM*
served as template for the reactions. Arrow indicates the ampliﬁca-
tion products of the expected sizes. Products spanning the genetic
tags are shown with or without prior digestion with BbsI or EcoNI,
respectively. Considering complete digestion of the LCMV-ARM–
derived PCR product by EcoNI, incomplete digestion by BbsI most
likely resulted from an inhibitory effect of PCR buffer that had been
present in the digestion reaction. Predicted fragment sizes are for
BbsI digestion: 595 and 411 nucleotides; for EcoNI digestion: 269 and
251 nucleotides. Undigested PCR products of the expected sizes are
indicated with arrows. Double-headed arrows indicate restriction
fragments of the expected sizes.
(E) BHK-21 cells (10
6 cells in M6 well) were infected with the
indicated dose combination of LCMV-ARM and rLCMV/INDG for 48
h. Total cellular RNA was collected and rLCMV/INDG RNA was
detected by RT-PCR as in (D). An arrow indicates the ampliﬁcation
product of the expected size.
Found at DOI: 10.1371/journal.ppat.0020051.sg006 (1.1MB EPS).
Figure S7. Indistinguishable CTL Response to LCMV-ARM and
rLCMV-ARM* Infection
(A) C57BL/6 mice were infected i.v. with 10
5 PFU LCMV-ARM or
rLCMV-ARM* and were killed on day 9 (same experiment as in
Figure 5C). The frequency of GP33- and of NP396-speciﬁc CD8
þ T
cells in the spleen of mice was determined by MHC class I tetramer
staining. Representative FACS plots of three mice per group are
shown [except for a single naive control mouse (none)]. Numbers in
the upper right quadrants indicate the percentage of epitope-speciﬁc
CD8
þ T cells within the total CD8
þ T cell population (mean 6 SD,
except for naive control).
(B and C) GP33-speciﬁc (B) and NP396-speciﬁc (C) cytolytic activity of
the same splenocytes as tested in (A). Symbols represent the mean 6
SD of three mice per group (except for the single naı ¨ve control). (B
and C) One representative of two independent experiments.
Found at DOI: 10.1371/journal.ppat.0020051.sg007 (408 KB EPS).
Figure S8. Inability of rLCMV/INDG to Establish Persistence in the
Central Nervous System of Adult Immunocompetent Mice
C57BL/6 mice were inoculated with 3 3 10
3 PFU rLCMV/INDG
intracerebrally, either in adulthood (‘‘adult’’) or within 24 h after
birth (‘‘neonatal’’). Two weeks later, all animals were killed and brain
RNA was processed for RT-PCR analysis. An NP-speciﬁc ampliﬁca-
tion product was obtained using the primers NP2223f and NP2743r,
as described in Materials and Methods. Each lane represents an
individual mouse.
Found at DOI: 10.1371/journal.ppat.0020051.sg008 (400 KB EPS).
Protocol S1. Supplementary Text
Explanatory text to Figure S1 (Rapid Elimination of Intracerebral
LCMV-ARM Infection by rLCMV/INDG-Induced Memory CTL),
Figure S3 (rLCMV/INDG-Induced Immune Protection Is Rapidly
Established), Figure S4 (Rapid and Potent nAb Response to rLCMV/
NJG Infection), Figure S6 (Generation and Molecular Character-
ization of rLCMV-ARM*), and Figure S7 (Indistinguishable CTL
Response to LCMV-ARM and rLCMV-ARM* Infection), with supple-
mentary references and supplementary methods.
Found at DOI: 10.1371/journal.ppat.0020051.sd001 (80 KB DOC).
Table S1. Serological Characterization of Wild-Type and Recombi-
nant LCM Viruses
Found at DOI: 10.1371/journal.ppat.0020051.st001 (36 KB DOC).
Accession Numbers
The GenBank (http://www.ncbi.nlm.nih.gov/Genbank) accession num-
bers for the complete sequences of the cDNA-derived recombinant S
segments in rLCMV/INDG, rLCMV/NJG, and rLCMV-ARM* are
DQ408670, DQ408671, and DQ458914, respectively.
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